Multicenter phase II clinical trial of nilotinib for patients with imatinib-resistant or -intolerant chronic myeloid leukemia from the East Japan CML study group evaluation of molecular response and the efficacy and safety of nilotinib

BACKGROUND: Nilotinib is a second-generation tyrosine kinase inhibitor that exhibits significant efficacy as first- or second-line treatment in patients with chronic myeloid leukemia (CML). We conducted a multicenter Phase II Clinical Trial to evaluate the safety and efficacy of nilotinib among Japa...

Descripción completa

Detalles Bibliográficos
Autores principales: Takahashi, Naoto, Miura, Masatomo, Kuroki, Jun, Mitani, Kinuko, Kitabayashi, Atsushi, Sasaki, Osamu, Kimura, Hideo, Imai, Kiyotoshi, Tsukamoto, Norifumi, Noji, Hideyoshi, Kondo, Takeshi, Motegi, Mutsuhito, Kato, Yuichi, Mita, Masayuki, Saito, Hajime, Yoshida, Chikashi, Torimoto, Yoshihiro, Kimura, Tomofumi, Wano, Yuji, Nomura, Jun, Yamamoto, Satoshi, Mayama, Ko, Honma, Riko, Sugawara, Tomohiro, Sato, Shinji, Shinagawa, Atsushi, Abumiya, Maiko, Niioka, Takenori, Harigae, Hideo, Sawada, Kenichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3994575/
https://www.ncbi.nlm.nih.gov/pubmed/24650752
http://dx.doi.org/10.1186/2050-7771-2-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3994575/
https://www.ncbi.nlm.nih.gov/pubmed/24650752
http://dx.doi.org/10.1186/2050-7771-2-6

Ejemplares similares